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Summary This survival study includes 20 breast cancer patients diagnosed during pregnancy and 15 patients
diagnosed during the lactation period. The survival rate of these patients is compared with that of ordinary
breast cancer patients taking stage of the disease, age and calendar-year at diagnosis into account. The
pregnancy group showed a significantly. poorer prognosis compared with the control groups. Only 3 out of 20
survived more than 4 years. The tendency of a worse prognosis for the lactation group than for the control
group was, however, not significant.
Breast cancer patients diagnosed during pregnancy and
lactation represent a special group. Therapeutic attitudes
have changed from regarding these patients as incurable
(Haagensen, 1956), to the more optimistic approach demon-
strated by Peters (1968) who concluded that their prognosis
is as favourable as that for the non-pregnant group.
The association of breast cancer with pregnancy and
lactation is uncommon and only a small number of cases
have been reported. Definitions of pregnancy and lactation
are rather wide. For example, Clark and Reid (1978) defined
their pregnant group as patients in whom symptoms deve-
loped or diagnosis was made during pregnancy or symptoms
developed before pregnancy; and the lactating group as
patients who developed breast cancer up to one year after
delivery. Peters (1968), on the other hand, included both the
pregnant and lactating patients in a single group.
Clinical stage of breast cancer at the time of diagnosis is
known to be prognostically important. The importance of
age as a prognostic factor is more controversial. One Norwe-
gian study (H0st & Lund, 1986), revealed a poorer prognosis
for younger patients (<35 years) than for patients aged 35-
49 years. Therefore age at diagnosis was included in the
present analysis. Since most studies concerning survival of
breast cancer patients diagnosed during pregnancy and the
lactation period lacked controls for these two factors, we
report here a study of prognosis in pregnant and lactating
patients separately, in comparison with control groups of
breast cancer patients drawn from the population-based
Norwegian Cancer Registry.
Patients and methods
During the period 1954-1981, 35 patients below 45 years of
age with breast cancer and coincident pregnancy or lactation
were treated at the Norwegian Radium Hospital. Treatment
of such cases of breast cancer has been centralized in this
hospital. We therefore believe that this study includes the
great majority of these cases in Norway in this period. At
the time when cancer was diagnosed 20 patients were
pregnant and 15 were lactating.
The survival rate of these patients was compared with
non-pregnant, non-lactating breast cancer patients randomly
drawn from the population-based Norwegian Cancer
Registry. Both the pregnancy group and the lactating group
had two sets of matched controls (Table I). One control
group for each case-group was not matched for stage at the
time of diagnosis in order to avoid possible over-matching.
To study the survival function of the different groups, the
method of Kaplan and Meier (1958) was used. The cumulat-
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ive intensities were estimated by the Nelson (1968) estimator.
The log-rank test was applied when testing differences
between groups.
Histological grading was carried out on all cases and for
one control per case matched on stage, calendar time and
age. In two cases the material was unsuitable and hence the
matching controls were not graded. Two or three specimens
were taken from each primary tumour. Slides stained with
haematoxylin and eosin were graded according to WHO
definitions (Scharff & Torloni, 1968).
The WHO grading is based on the following factors:
Tubule formation, hyperchromatism, mitosis and irregularity
of size, shape and staining of nuclei. A number system is
used, from I to 3 for each factor according to the extent of
the changes. These numbers are then added together, a total
of 3-5 indicating low malignancy (grade I), 6-7 intermediate
malignancy (grade II) and 8-9 high malignancy (grade III).
The Norwegian Cancer Registry definition of stage was
used:
Stage I: Tumours of all sizes confined to the breast.
(Except cases belonging to stage III).
Stage II: Tumour in the breast with metastases to the
axillary lymph nodes.
Stage III: Tumour in the breast with direct extension to
the skin or chest wall (with or without axillary lymph
node metastases).
Stage IV: Tumour in the breast with distant metastases.
When cancer was diagnosed, the patients were asked by
their doctors about the exact time they had noticed the first
symptom. The difference between this point of time and the
time of diagnosis was defined as diagnosis delay.
Results
The median age was 33 years (95% CI: 31, 37) in the
pregnancy group and 36 years (95% CI: 31, 40) in the
lactating group.
In the pregnancy group the median diagnosis delay was
2.5 months (95% CI: 1, 4.5) and in the lactating group 6
months (95% CI: 2.5, 12). The majority of women in the
lactating group gave the time of the first symptom as the
time of delivery.
Figure 1 shows survival in per cent by time (months) after
diagnosis in the pregnancy group and the two control
groups. More than 60% of the pregnant breast cancer
patients died within 2 years from diagnosis and only 3 out of
20 were alive 4 years after diagnosis. The survival rate is
significantly lower than in the control group 1, (P<0.05).
The similarity in survival rate between control groups lp and
IIp shows that anxiety about overmatching was unnecessary.
Figure I demonstrates that pregnancy is a strong prognostic
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Table I Definition of patients and controls
Group Number Description
Pregnancy 20 Breast cancer diagnosed during pregnancy.
Control Ip 40 2 Matched controls per individual in the pregnancy group.
Match criteria: Same stage at diagnosis.
Diagnosed the same calendar-year+2 years.
Diagnosed at same age+2 years.
Control IIp 40 2 Matched controls per individual in the pregnancy group.
Match criteria: Diagnosed the same calendar-year+2 years.
Diagnosed at same age+2 years.
Lactating 15 Breast cancer diagnosed during lactation period.
Control IL 30 2 Matched controls per individual in the lactation group.
Match criteria: Same stage at diagnosis.
Diagnosed the same calendar-year+2 years.
Diagnosed at same age+2 years.
Control IIL 30 2 Matched controls per individual in the lactation group.
Match criteria: Diagnosed the same calendar-year+2 years.
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Figure 1 Survival (%) by time after diagnosis. Pregnancy group Figure 2 Cumulative death intensity in pregnancy group plotted
versus two control groups. against cumulative death intensity in control group Ip for each 6
months of observation since diagnosis.
factor even when we have matched for stage at time of uu
diagnosis. In Figure 2 the cumulative death intensity in the
pregnancy group is plotted against the cumulative death
intensity for the control group Ip for each 6 months of
observation since diagnosis up to 48 months. The plot 80
corresponds with a linear curve. This means that the death
intensity in the pregnancy group is a constant multiplied by
the death intensity in the control group at each point of time
since diagnosis. The relative death risk, as defined by g 60
Breslow and Day (1980), is then equal to this constant. The
risk of death for breast cancer patients diagnosed during >
pregnancy is 3.1 times higher than for other cancer patients ,
with the same distribution of stage at diagnosis, age and 40
calendar-year at time of diagnosis.
Figure 3 shows the survival function for the lactation
group and its two control groups (IL' I1L). There is a
tendency towards poorer prognosis for the lactation group 20
but the difference is not significant.
In Table II some clinical findings are listed. At the time of
diagnosis 4 out of 20 women in the pregnancy group were
nulliparous while 2 out of 15 in the lactation group had not 0
had anv children before. In the nreanancv oroun 11 out of 0
20 patients were in the third trimester when the breast cancer Months after diagnosis
was discovered. Therapeutic abortion was performed in 5 Figure 3 Survival (%) by time after diagnosis. Lactating group
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Table 11 Number of cases grouped according to clinical
stage, trimester and parity at time of diagnosis
Pregnancy Lactating
group group




Trimester First 5 -
Second 4
Third 11 -










Group I II III for grading
Pregnancy 5 5 9 1
Control IP 6 8 5
Lactating 4 8 2 1
Control IL 4 5 5
pregnancy and the lactating groups the majority of the
patients presented in an advanced clinical stage. Six out of
20 and 3 out of 15 of the cases respectively were diagnosed
as being in stage I while - 50% of all breast cancer cases
diagnosed in Norway presented in stage I in this age-group
and time period.
In the pregnancy group 9 out of 19 had histologically
highly aggressive tumours (grade III), compared with 5 out
of 19 in control group Ip (Table III). In the lactating group 2
out of 14 were grade III compared with 5 out of 14 in the
control group IL. There was no significant difference in the
distribution of grade between cases and their controls.
It was notable that 5 of the carcinomas (2 in the
pregnancy group and 3 in the lactating group) were of the
inflammatory type. The clinical picture had been characteris-
tic and the histological features were dominated by extensive
necrosis and inflammation.
Discussion
Our patients were either pregnant or breast feeding at the
time of diagnosis. The results show the importance of
separating these patients into two groups. Pregnant women
with breast cancer have a very poor prognosis in our study.
Contrary to Donegan's (1979) statement, we found that
pregnancy is also an important prognostic factor when the
stage at time of diagnosis is taken into account.
It is remarkable that the poorer prognosis is present at
each point of time since diagnosis. This means that the
relative risk of dying is constant by time since diagnosis. A
possible diagnostic delay would not be expected to act in this
way nor does the median patient's delay of 2.5 months in the
pregnancy group suggest that the poorer prognosis in this
group is caused by an especially long delay.
It cannot be claimed that the lactating group has a poorer
prognosis than the control groups although there was a
tendency in this direction. This tendency might be explained
by the fact that pregnancy necessarily precedes a lactation
period.
Our results for the pregnancy group support very early
reports and contrast to some extent those of Peters (1968)
and Clark and Reid (1978). It is possible that some of this
discrepancy results from their wide definitions of pregnancy
and lactation which may mask the effect of pregnancy on the
prognosis.
Histological grading is subjective, but has nevertheless
been shown to be strongly related to prognosis (Freedman et
al., 1979). The pregnancy group in our study had a high
proportion (9/19) of grade III tumours, but did not differ
significantly from the distribution of high and low grade
tumours among the matched controls. Carcinomas of the
inflammatory type are usually associated with a poor
prognosis (Bosetti et al., 1981). The distribution was two
carcinomas of this type in the pregnancy group and three in
the lactating group and was not the explanation of the
observed difference in prognosis between the two groups.
Donegan (1979) described several marked hormone
changes during pregnancy which could enhance the growth
of mammary carcinoma. In this connection it is interesting
that the majority in both the pregnancy group (16/20) and
the lactating group (13/15) were multiparous and conse-
quently had experienced such hormone changes previously.
This raises questions about latency period and why earlier
pregnancies did not have a tumour promoting effect giving
rise to symptoms. The mechanism may act only under
certain circumstances or in an advanced stage of the disease.
We thank Dr Ashton Miller for valuable comments during
preparation of this manuscript.
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